This is a preview of subscription content, log in via an institution to check access.
Reference
Gutkind S, et al. Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs. Clinical Infectious Diseases : 16 May 2019. Available from: URL: http://doi.org/10.1093/cid/ciz384
Rights and permissions
About this article
Cite this article
HCV treatment models for PWID: finding cost-effective options. PharmacoEcon Outcomes News 829, 15 (2019). https://doi.org/10.1007/s40274-019-5929-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5929-z